Soo Han Bae
Overview
Explore the profile of Soo Han Bae including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
5713
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim H, Jeong H, Jeong M, Won H, Lee G, Bae S, et al.
Int J Biol Sci
. 2024 May;
20(7):2592-2606.
PMID: 38725855
Transcriptional coactivator with a PDZ-binding motif (TAZ) plays a key role in normal tissue homeostasis and tumorigenesis through interaction with several transcription factors. In particular, TAZ deficiency causes abnormal alveolarization...
2.
Lee C, Kwak S, Han J, Shin J, Yoo B, Lee Y, et al.
Eur Respir J
. 2024 Feb;
63(5).
PMID: 38359963
Background: We previously identified ezetimibe, an inhibitor of Niemann-Pick C1-like intracellular cholesterol transporter 1 and European Medicines Agency-approved lipid-lowering agent, as a potent autophagy activator. However, its efficacy against pulmonary...
3.
Lee C, Cha Y, Bae S, Kim Y
BMJ Open Respir Res
. 2023 Nov;
10(1).
PMID: 37940356
Introduction: Cholesterol is an irreplaceable nutrient in pulmonary metabolism; however, studies on high-density lipoprotein cholesterol (HDL-C) levels have shown conflicting results regarding lung function. Therefore, we investigated the association between...
4.
Kim W, Min S, Kim S, Kang S, An S, Criado-Hidalgo E, et al.
Nat Mater
. 2023 Oct;
23(2):290-300.
PMID: 37845321
Measuring cellular and tissue mechanics inside intact living organisms is essential for interrogating the roles of force in physiological and disease processes. Current agents for studying the mechanobiology of intact,...
5.
Kim J, Kim M, Han T, Lee J, Kim S, Kim H, et al.
Cell Death Dis
. 2023 Aug;
14(8):567.
PMID: 37633973
Ferroptosis, a type of cell death induced by lipid peroxidation, has emerged as a novel anti-cancer strategy. Cancer cells frequently acquire resistance to ferroptosis. However, the underlying mechanisms are poorly...
6.
Lee D, Jee J, Lee Y, Kim D, Bang J, Lee H, et al.
Dig Liver Dis
. 2023 Jun;
55(11):1521-1532.
PMID: 37380586
Nonalcoholic steatohepatitis (NASH) is associated with imbalance of gut microbiome, indicating participation of gut environment in hepatic health status. Therefore, modulating gut environment via fecal microbiota transplantation (FMT) is a...
7.
Seo S, Lee D, Lee Y, Cho K, Park H, Lee H, et al.
Gastroenterol Rep (Oxf)
. 2022 Aug;
10:goac037.
PMID: 35982712
Background: Ursodeoxycholic acid (UDCA), statins, and ezetimibe (EZE) have demonstrated beneficial effects against non-alcoholic fatty liver disease (NAFLD). We investigated the efficacy of the combination of UDCA and the mix...
8.
Park K, Lim H, Kim J, Hwang Y, Lee Y, Bae S, et al.
Nat Commun
. 2022 Mar;
13(1):1300.
PMID: 35288580
Although autophagy is critical for pancreatic β-cell function, the role and mechanism of mitophagy in β-cells are unclear. We studied the role of lysosomal Ca in TFEB activation by mitochondrial...
9.
Lee D, Park J, Lee Y, Bae S
Redox Biol
. 2022 Jan;
50:102235.
PMID: 35091323
Hepatic lipotoxicity is a crucial factor in nonalcoholic steatohepatitis resulting from excessive saturated fatty acid-induced reactive oxygen species (ROS)-mediated cell death, which is associated with the accumulation of endoplasmic reticulum...
10.
Ran Kim E, Park J, Kim J, Oh J, Oh I, Choi D, et al.
Hepatology
. 2021 Nov;
75(6):1523-1538.
PMID: 34773257
Background And Aims: Currently there is no Food and Drug Administration-approved drug to treat NAFLD and NASH, the rates of which are increasing worldwide. Although NAFLD/NASH are highly complex and...